Education
About Us
Working with TipRanks
Follow Us
Glenmark Life Sciences Limited (IN:GLS)
:GLS
Total Valuation
Glenmark Life Sciences Limited has a market cap or net worth of ₹124.09B. The enterprise value is ₹45.50B.
Market Cap₹124.09B
Enterprise Value₹45.50B
Share Statistics
Glenmark Life Sciences Limited has 122,629,150 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding122,629,150
Owned by Insiders―
Owned by Institutions―
Financial Efficiency
Glenmark Life Sciences Limited’s return on equity (ROE) is 0.20 and return on invested capital (ROIC) is 27.74%.
Return on Equity (ROE)0.20
Return on Assets (ROA)0.17
Return on Invested Capital (ROIC)27.74%
Return on Capital Employed (ROCE)0.37
Revenue Per Employee11.34M
Profits Per Employee3.13M
Employee Count2,014
Asset Turnover0.80
Inventory Turnover1.56
Valuation Ratios
The current PE Ratio of Glenmark Life Sciences Limited is 20.43. Glenmark Life Sciences Limited’s PEG ratio is 1.48.
PE Ratio20.43
PS Ratio0.00
PB Ratio2.25
Price to Fair Value4.12
Price to FCF33.62
Price to Operating Cash Flow15.36
PEG Ratio1.48
Income Statement
In the last 12 months, Glenmark Life Sciences Limited had revenue of 22.83B and earned 4.71B in profits. Earnings per share was 38.43.
Revenue22.83B
Gross Profit12.43B
Operating Income8.98B
Pretax Income6.31B
Net Income4.71B
EBITDA6.86B
Earnings Per Share (EPS)38.43
Cash Flow
In the last 12 months, operating cash flow was 526.12M and capital expenditures 0.00, giving a free cash flow of 526.12M billion.
Operating Cash Flow526.12M
Free Cash Flow526.12M
Free Cash Flow per Share4.29
Dividends & Yields
Glenmark Life Sciences Limited pays an annual dividend of ₹22.5, resulting in a dividend yield of 3.96%
Dividend Per Share₹22.5
Dividend Yield3.96%
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta0.69
52-Week Price Change20.95%
50-Day Moving Average1.06K
200-Day Moving Average1.07K
Relative Strength Index (RSI)55.86
Average Volume (3m)4.96K
Important Dates
Glenmark Life Sciences Limited upcoming earnings date is Aug 8, 2025, Before Open (Confirmed).
Last Earnings DateMay 15, 2025
Next Earnings DateAug 8, 2025
Ex-Dividend DateOct 17, 2023
Financial Position
Glenmark Life Sciences Limited as a current ratio of 4.37, with Debt / Equity ratio of 0.91%
Current Ratio4.37
Quick Ratio2.85
Debt to Market Cap0.00
Net Debt to EBITDA-0.41
Interest Coverage Ratio580.80
Taxes
In the past 12 months, Glenmark Life Sciences Limited has paid 1.60B in taxes.
Income Tax1.60B
Effective Tax Rate0.25
Enterprise Valuation
Glenmark Life Sciences Limited EV to EBITDA ratio is 13.60, with an EV/FCF ratio of 32.81.
EV to Sales4.09
EV to EBITDA13.60
EV to Free Cash Flow32.81
EV to Operating Cash Flow22.57
Balance Sheet
Glenmark Life Sciences Limited has ₹3.02B in cash and marketable securities with ₹0.00 in debt, giving a net cash position of -₹3.02B billion.
Cash & Marketable Securities₹3.02B
Total Debt₹0.00
Net Cash-₹3.02B
Net Cash Per Share-₹24.59
Tangible Book Value Per Share₹189.13
Margins
Gross margin is 53.08%, with operating margin of 39.33%, and net profit margin of 20.62%.
Gross Margin53.08%
Operating Margin39.33%
Pretax Margin27.65%
Net Profit Margin20.62%
EBITDA Margin30.06%
EBIT Margin27.72%
Analyst Forecast
The average price target for Glenmark Life Sciences Limited is ―, which is 11.43% higher than the current price. The consensus rating is ―
Price Target―
Price Target Upside―
Analyst Consensus―
Analyst Count0
Revenue Growth Forecast―
EPS Growth Forecast―